Announcements Trials
Browse Landscape

Phase

Phase NA 18Phase 2 3Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1CNS 1

Conditions

Prostatic Neoplasms 103Carcinoma, Renal Cell 30Urinary Bladder Neoplasms 22Breast Neoplasms 20Carcinoma, Transitional Cell 11Lung Neoplasms 10Melanoma 9Neoplasms 8Kidney Neoplasms 8Neoplasm Metastasis 7Colonic Neoplasms 7Sarcoma 6Pancreatic Neoplasms 6Ovarian Neoplasms 6Metastatic Castration-resistant Prostate Cancer 6Head and Neck Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Uterine Cervical Neoplasms 4Stomach Neoplasms 4Brain Neoplasms 4Osteosarcoma 3Diabetes Mellitus 3Colorectal Neoplasms 3Carcinoma, Squamous Cell 3Carcinoma, Hepatocellular 3Urologic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Rectal Neoplasms 2Prostatic Hyperplasia 2

Interventions

Lisinopril 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Radiation Injuries × Genitourinary × Clear all
NCT05530655 2026-01-13

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

University of Rochester

Phase EARLY_PHASE1 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms, Radiation Injuries

Data powered by HemOnc (CC BY 4.0) Colophon âš¡